Bristol-Myers Squibb Co (NYSE:BMY)’s traded shares stood at 1.78 million during the latest session, with the company’s beta value hitting 0.41. At the last check today, the stock’s price was $49.78, to imply an increase of 0.34% or $0.17 in intraday trading. The BMY share’s 52-week high remains $63.33, putting it -27.22% down since that peak but still an impressive 20.95% since price per share fell to its 52-week low of $39.35. The company has a valuation of $101.31B, with an average of 17.05 million shares in intraday trading volume over the past 10 days and average of 13.91 million shares over the past 3 months.
Analysts have given a consensus recommendation of Hold for Bristol-Myers Squibb Co (BMY), translating to a mean rating of 2.64. Of 14 analyst(s) looking at the stock, 0 analyst(s) give BMY a Sell rating. 0 of those analysts rate the stock as Overweight while 9 advise Hold as 5 recommend it as a Buy. 0 analyst(s) have given it an Underweight rating. Estimates put the company’s current-quarter earnings per share at 1.68.
Bristol-Myers Squibb Co (NYSE:BMY) trade information
After registering a 0.34% upside in the latest session, Bristol-Myers Squibb Co (BMY) has traded red over the past five days. The 5-day price performance for the stock is 3.92%, and -16.48% over 30 days. With these gigs, the year-to-date price performance is -11.99%. Short interest in Bristol-Myers Squibb Co (NYSE:BMY) saw shorts transact 30.03 million shares and set a 2.19 days time to cover.
The extremes give us $61 and $68 for target low and target high price respectively. As such, BMY has been trading -36.6% off suggested target high and -22.54% from its likely low.
Bristol-Myers Squibb Co (BMY) estimates and forecasts
The rating firms project that company’s revenue will shrink -4.41% compared to the previous financial year.
Revenue forecast for the current quarter as set by 17 analysts is 11.31B. Meanwhile, for the current quarter, a total of 16 analyst(s) estimate revenue growth to 11.63B.Earnings reports from the last fiscal year show that sales brought in 12.2B and 11.89B respectively in the corresponding quarters. In this case, analysts estimate current quarter sales to fall -7.29% before dropping -2.16% in the following quarter.
BMY Dividends
Bristol-Myers Squibb Co has its next earnings report out on 2025-Apr-23. However, it is important to take into account that this dividend yield ratio is just an indicator to only serve the purpose of guidance. Investors interested to invest in the stock should ponder company’s other fundamental and operations related aspects too. Bristol-Myers Squibb Co has a forward dividend ratio of 2.44, with the share yield ticking at 4.90% to continue the rising pattern observed over the past year. The company’s average dividend yield trailing the past 5-year period is 3.55%.
Bristol-Myers Squibb Co (NYSE:BMY)’s Major holders
Bristol-Myers Squibb Co insiders hold 0.07% of total outstanding shares, with institutional holders owning 80.59% of the shares at 80.65% float percentage. In total, 80.59% institutions holds shares in the company, led by VANGUARD GROUP INC. As of 2024-06-30, the company held over 186.57 million shares (or 9.2043% of shares), all amounting to roughly $7.75 billion.
The next major institution holding the largest number of shares is BLACKROCK INC. with 158.66 million shares, or about 7.8273% of shares outstanding. As of the market price on 2024-06-30, these shares were worth $6.59 billion.
We also have VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund and VANGUARD INDEX FUNDS-Vanguard 500 Index Fund as the top two Mutual Funds with the largest holdings of the Bristol-Myers Squibb Co (BMY) shares. Going by data provided on Dec 31, 2024 , VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund holds roughly 63.59 shares. This is just over 3.12% of the total shares, with a market valuation of $3.17 billion. Data from the same date shows that the other fund manager holds a little less at 54.9, or 2.70% of the shares, all valued at about 2.74 billion.
